Cooper Companies Stock (NASDAQ:COO)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$67.69

52W Range

$58.89 - $89.83

50D Avg

$64.68

200D Avg

$72.72

Market Cap

$13.17B

Avg Vol (3M)

$2.54M

Beta

0.87

Div Yield

-

COO Company Profile


The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

16,000

IPO Date

Jan 21, 1983

Website

COO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceOct 25Oct 24Oct 23
Coopervision Segment$2.74B$2.61B$2.42B
Coopersurgical Segment$1.35B$1.29B$1.17B
CooperVision Segment--$2.42B
CooperSurgical Segment--$1.17B

Fiscal year ends in Oct 25 | Currency in USD

COO Financial Summary


Oct 25Oct 24Oct 23
Revenue$4.09B$3.90B$3.59B
Operating Income$682.90M$705.70M$533.10M
Net Income$374.90M$392.30M$294.20M
EBITDA$666.50M$1.07B$885.90M
Basic EPS$1.87$1.97$1.49
Diluted EPS$1.87$1.96$1.48

Fiscal year ends in Oct 25 | Currency in USD

Latest Earnings Call Transcripts


Q2 26Jun 04, 26 | 12:00 AM
Q1 26Mar 06, 26 | 5:00 PM
Q4 25Dec 04, 25 | 5:00 PM

Peer Comparison


TickerCompany
SNNSmith & Nephew plc
FMSFresenius Medical Care AG & Co. KGaA
TEMTempus AI, Inc.
HOLXHologic, Inc.
ICLRICON Public Limited Company
NBIXNeurocrine Biosciences, Inc.
UHSUniversal Health Services, Inc.
SMMTSummit Therapeutics Inc.
SOLVSolventum Corporation
DOCSDoximity, Inc.